| Literature DB >> 28930689 |
Charu Mehta1, Kirby D Johnson1, Xin Gao1, Irene M Ong2, Koichi R Katsumura1, Skye C McIver1, Erik A Ranheim3, Emery H Bresnick4.
Abstract
Hematopoietic development requires the transcription factor GATA-2, and GATA-2 mutations cause diverse pathologies, including leukemia. GATA-2-regulated enhancers increase Gata2 expression in hematopoietic stem/progenitor cells and control hematopoiesis. The +9.5-kb enhancer activates transcription in endothelium and hematopoietic stem cells (HSCs), and its deletion abrogates HSC generation. The -77-kb enhancer activates transcription in myeloid progenitors, and its deletion impairs differentiation. Since +9.5-/- embryos are HSC deficient, it was unclear whether the +9.5 functions in progenitors or if GATA-2 expression in progenitors solely requires -77. We further dissected the mechanisms using -77;+9.5 compound heterozygous (CH) mice. The embryonic lethal CH mutation depleted megakaryocyte-erythrocyte progenitors (MEPs). While the +9.5 suffices for HSC generation, the -77 and +9.5 must reside on one allele to induce MEPs. The -77 generated burst-forming unit-erythroid through the induction of GATA-1 and other GATA-2 targets. The enhancer circuits controlled signaling pathways that orchestrate a GATA factor-dependent blood development program.Entities:
Keywords: GATA-2; enhancer; erythroid; hematopoiesis; mouse model; myeloid; progenitor
Mesh:
Substances:
Year: 2017 PMID: 28930689 PMCID: PMC5618720 DOI: 10.1016/j.celrep.2017.08.090
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423